William Tembo: Advancing Stroke Care by Validating Acute Ischemic Treatment
William Tembo, Stroke Research Fellow, Acute Care Research Coordinator at University of Minnesota, shared on LinkedIn:
“Trial thursday
Clinical Vignette
A 67 year old right handed man was at a park eating a burger with his family when he suddenly developed difficulty speaking and mild weakness of the right arm at approximately 1:00 PM.
Over the next 20 minutes, his symptoms progressed to dense right sided weakness and worsening speech difficulty, prompting his family to call emergency medical services.
He arrived at the emergency department at 1:40 PM.
On examination, he was alert with nonfluent speech, right facial droop, and dense weakness of the right arm and leg, with an NIH Stroke Scale score of 14.
A noncontrast CT scan of the head performed on arrival showed no evidence of intracranial hemorrhage, and a diagnosis of acute ischemic stroke was made.
Questions
- What is the appropriate treatment option in this patient?
- Do the potential benefits outweigh the risks?
Study Design
These were the exact questions that led to the NINDS rt-PA Stroke Trial, which sought to determine whether early thrombolysis could improve outcomes in acute ischemic stroke despite the risk of intracerebral hemorrhage.
The NINDS trial was a randomized, double blind, placebo controlled study that enrolled patients with acute ischemic stroke who could be treated within three hours of symptom onset.
Patients were assigned to receive either intravenous alteplase or placebo, with outcomes assessed at three months using measures of functional recovery.
Results
Among patients presenting with acute ischemic stroke within three hours of symptom onset, those treated with alteplase were at least 30 percent more likely to have minimal or no disability at three months compared to those receiving placebo.
This benefit was seen across multiple functional outcome measures.
However, treatment was associated with an increased risk of symptomatic intracerebral hemorrhage, occurring in approximately 6.4 percent of patients in the tPA group versus 0.6 percent in the placebo group.
Despite this increased bleeding risk, overall mortality was not significantly different between the two groups.
My Takeaway
The trial changed stroke care by showing that acute ischemic stroke can be treated, not just observed.
It taught us that time sensitive reperfusion can improve functional outcomes, even though that benefit may come with real bleeding risk.
The lasting lesson is that in the right patient, treated quickly and appropriately, the potential benefit can outweigh the risk.
Disclaimer
This is a hypothetical clinical vignette created for educational purposes and does not represent a real patient.
The views expressed are my own and do not represent any institution.
This content is not medical advice.”
Title: Tissue Plasminogen Activator for Acute Ischemic Stroke
Authors: The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group
Read the Full Article on NEJM
Stay updated with Hemostasis Today.
-
Mar 20, 2026, 17:37Renjith Vijayakumar Selvarani: New Nanoparticle Approach Clears Brain Plaque and Restores Memory
-
Mar 20, 2026, 17:35Bawan Ahmed: New Evidence May Shift DOAC Choice in Acute DVT Management
-
Mar 20, 2026, 17:17Angelo Cascio Rizzo: CTA-Based Plaque RADS Improves Risk Stratification in ESUS
-
Mar 20, 2026, 17:09Clinical Practice Guidelines for Platelet Transfusion in Non-Surgical and Non-Traumatic Settings – CEBaP
-
Mar 20, 2026, 17:07The Rich Heterogeneity of Platelets and Its Vital Shifts Across Disease States – RPTH
-
Mar 20, 2026, 17:05Pierre Fontana: Launching the European Interuniversity Certificate in Clinical Haemostasis
-
Mar 20, 2026, 16:49Wolfgang Miesbach: A Pivotal Step Forward for Patients with von Willebrand Disease Across All Subtypes
-
Mar 20, 2026, 16:42Charlie Zhou: Exploring the Potential of Immune Reset Therapies in Autoimmune Cytopenias
-
Mar 20, 2026, 16:40Kate G.: Moving Beyond Being ‘Just a Carrier’